Creyon Bio has announced a global research and licensing agreement with Eli Lilly and Company to develop RNA-targeted oligonucleotide (oligo) therapies.

Creyon Bio 宣布与礼来公司达成一项全球研究和许可协议，以开发针对 RNA 的寡核苷酸 (oligo) 疗法。

The collaboration aims to accelerate the discovery and development of treatments for a wide range of diseases by combining Creyon’s proprietary AI-powered oligo engineering platform with Lilly’s drug development expertise.

该合作旨在通过将Creyon专有的AI驱动的寡核苷酸工程平台与Lilly的药物开发专业知识相结合，加速针对多种疾病的治疗发现和开发进程。

The partnership will see Creyon design and optimise RNA-targeted oligos using its artificial intelligence-driven platform, which applies quantum chemistry principles to speed up the drug development process.

该合作将使Creyon利用其人工智能驱动的平台设计和优化RNA靶向寡核苷酸，该平台应用量子化学原理来加速药物开发过程。

As part of the agreement, Creyon will receive an initial payment of $13 million, which includes both cash and equity investment. The company is also eligible to earn over $1 billion in additional payments tied to development and commercial milestones.

根据协议，Creyon将获得1300万美元的首付款，其中包括现金和股权投资。该公司还有资格获得超过10亿美元的额外付款，这些付款与开发和商业里程碑相关。

Lilly will gain exclusive rights to lead therapeutic candidates identified through the collaboration. Upon achieving certain milestones, Lilly will assume responsibility for further research, development and commercialisation efforts.

礼来将获得通过合作确定的主导治疗候选药物的独家权利。在达到某些里程碑后，礼来将承担进一步的研究、开发和商业化工作。

The deal represents a key step forward for Creyon as it works to expand its pipeline of RNA-based therapies targeting both rare and common conditions.

该交易代表着Creyon在努力扩展针对罕见和常见疾病的基于RNA的治疗管道方面迈出了关键一步。

This approach is intended to reduce reliance on traditional trial-and-error methods, enabling faster identification of promising drug candidates.

这种方法旨在减少对传统试错方法的依赖，从而更快地识别出有潜力的药物候选者。